Roth Capital lowered the firm’s price target on Beauty Health (SKIN) to $2 from $2.50 and keeps a Buy rating on the shares. The firm is updating its model after the company’s Q1 results while noting that Beauty Health continues to face competitive pressures particularly in the lower end of the market where knock-offs and scaled-down models suffice for cost-sensitive providers, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKIN:
- Beauty Health Receives Nasdaq Notice on Bid Price
- Beauty Health Earnings Call: Profits Up, Sales Strain
- Rebranding Risk: How SkinHealth Systems’ Name Change Could Erode Brand Equity, Raise Marketing Costs, and Pressure Margins
- Beauty Health announces departure of chief revenue officer
- Beauty Health price target lowered to $1 from $1.50 at Canaccord